Tag: M.W=200-250

Hack, Daniel published the artcileCombining silver- and organocatalysis: an enantioselective sequential catalytic approach towards pyrano-annulated pyrazoles, Name: 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone, the publication is Chemical Communications (Cambridge, United Kingdom) (2015), 51(12), 2266-2269, database is CAplus and MEDLINE.

A one-pot asym. Michael addition/hydroalkoxylation sequence, catalyzed by a sequential catalytic system consisting of a squaramide and a silver salt, provides a new series of chiral pyrano-annulated pyrazole derivatives, e.g., I, in excellent yields (up to 95%) and high enantioselectivities (up to 97% ee).

Chemical Communications (Cambridge, United Kingdom) published new progress about 14580-22-4. 14580-22-4 belongs to pyrazoles-derivatives, auxiliary class Organic Pigment, name is 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone, and the molecular formula is C10H9ClN2O, Name: 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Mahajan, Suruchi published the artcileEnantioselective synthesis of pyrazolone α-aminonitrile derivatives via an organocatalytic Strecker reaction, COA of Formula: C10H9ClN2O, the publication is Chemical Communications (Cambridge, United Kingdom) (2017), 53(49), 6633-6636, database is CAplus and MEDLINE.

A new organocatalytic enantioselective Strecker reaction of pyrazolone-derived ketimine electrophiles was developed. Using pseudo-enantiomeric squaramide catalysts the nucleophilic 1,2-addition of trimethylsilyl cyanide to the ketimines efficiently provided a direct entry to both enantiomers of pyrazolone α-aminonitrile derivatives at will in good yields and high enantioselectivities for a wide variety of substrates.

Chemical Communications (Cambridge, United Kingdom) published new progress about 14580-22-4. 14580-22-4 belongs to pyrazoles-derivatives, auxiliary class Organic Pigment, name is 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone, and the molecular formula is C10H9ClN2O, COA of Formula: C10H9ClN2O.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Dong, Daoqing published the artcileDirect synthesis of sulfonated or sulfenylated pyrazolones mediated by KIO₃ and their anti-microbial activity, Quality Control of 14580-22-4, the publication is Youji Huaxue (2019), 39(11), 3190-3198, database is CAplus.

A facile and efficient method for the synthesis of sulfonated or sulfenylated pyrazolones catalyzed by KIO₃ was established. A variety of desired products were obtained in moderate to high yields. This methodol. was conducted under mild reaction conditions without requiring any metal. Control experiments showed that the mechanism of this reaction was different from previous KIO₃-catalyzed reactions. Some of these desired products showed high inhibitory activity against V. mali and B. cinerea.

Youji Huaxue published new progress about 14580-22-4. 14580-22-4 belongs to pyrazoles-derivatives, auxiliary class Organic Pigment, name is 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone, and the molecular formula is C10H9ClN2O, Quality Control of 14580-22-4.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Li, Yingjun published the artcileN-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors, Related Products of pyrazoles-derivatives, the publication is ACS Medicinal Chemistry Letters (2015), 6(5), 543-547, database is CAplus and MEDLINE.

A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-Raf^V600E with low nanomolar IC₅₀ values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-Raf^V600E mutation while being significantly less potent to the cells with B-Raf^WT. The compounds also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-Raf^V600E mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compound for further anticancer drug discovery.

ACS Medicinal Chemistry Letters published new progress about 1363381-82-1. 1363381-82-1 belongs to pyrazoles-derivatives, auxiliary class Other Aromatic Heterocyclic,Bromide,Ether, name is 5-Bromo-3-methoxy-1H-pyrazolo[3,4-b]pyridine, and the molecular formula is C7H6BrN3O, Related Products of pyrazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Pfefferkorn, Jeffrey A. published the artcileP2Y₁ receptor antagonists as novel antithrombotic agents, Related Products of pyrazoles-derivatives, the publication is Bioorganic & Medicinal Chemistry Letters (2008), 18(11), 3338-3343, database is CAplus and MEDLINE.

The P2Y₁ and P2Y₁₂ purinergic receptors are responsible for mediating ADP (ADP) dependent platelet aggregation. Evidence from P2Y₁ knockout studies as well as from nucleotide-based small mol. P2Y₁ antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y₁ antagonists that are potent and orally bioavailable.

Bioorganic & Medicinal Chemistry Letters published new progress about 14580-22-4. 14580-22-4 belongs to pyrazoles-derivatives, auxiliary class Organic Pigment, name is 1-(2-Chlorophenyl)-3-methyl-5-pyrazolone, and the molecular formula is C10H9ClN2O, Related Products of pyrazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Anderson, Niall A. published the artcileSynthesis and determination of absolute configuration of a non-peptidic α_vβ₆ integrin antagonist for the treatment of idiopathic pulmonary fibrosis, Safety of 3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenylboronic acid, the publication is Organic & Biomolecular Chemistry (2016), 14(25), 5992-6009, database is CAplus and MEDLINE.

A diastereoselective synthesis of I, a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis, which is currently undergoing Phase I trials is reported. The key steps in the synthesis involved alkylation of 2-methylnaphthyridine with (R)-N-Boc-3-(iodomethyl)-pyrrolidine, and an asym. Rh-catalyzed addition of an arylboronic acid to a 4-(N-pyrrolidinyl)crotonate ester. The overall yield of the seven linear step synthesis is 8% and the product is obtained in <99.5% ee proceeding with 80% de. The absolute configuration of I is established by an alternative asym. synthesis involving alkylation of an arylacetic acid using Evans oxazolidinone chem., acylation using the resulting 2-arylsuccinic acid, and reduction The absolute configuration of the benzylic asym. center is established as (S).

Organic & Biomolecular Chemistry published new progress about 1025735-46-9. 1025735-46-9 belongs to pyrazoles-derivatives, auxiliary class Pyrazole,Boronic acid and ester,Benzene,Boronic Acids, name is 3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenylboronic acid, and the molecular formula is C11H13BN2O2, Safety of 3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenylboronic acid.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Hu, Liming published the artcileDesign, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors, HPLC of Formula: 1416437-27-8, the publication is Bioorganic & Medicinal Chemistry Letters (2016), 26(23), 5830-5835, database is CAplus and MEDLINE.

A series of 4-((pyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyrazol-1-yl)phenyl-3-benzamide derivatives and 4-((imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl)phenyl-3-benzamide derivatives were designed, synthesized as new BCR-ABL tyrosine kinase inhibitors by using combinational strategies of scaffold hopping and conformational constraint. These new compounds were screened for BCR-ABL1 kinase inhibitory activity, and most showed good inhibitory activity against BCR-ABL1 kinase. One of the most potent compounds I strongly suppressed BCR-ABL1 kinase with IC₅₀ value of 8.5 nM. The tested compounds I (and a second compound) showed strong inhibitory activities against K562 with IC₅₀ value of less than 2 nM. Mol. docking studies indicated that these compounds fitted well with the active site of BCR-ABL1 protein. The results showed these inhibitors may serve as lead compounds for developing new drugs targeted at BCR-ABL kinase.

Bioorganic & Medicinal Chemistry Letters published new progress about 1416437-27-8. 1416437-27-8 belongs to pyrazoles-derivatives, auxiliary class Other Aromatic Heterocyclic,Boronic acid and ester,Boronate Esters,Boronic acid and ester, name is 6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine, and the molecular formula is C12H16BN3O2, HPLC of Formula: 1416437-27-8.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Barlaam, Bernard published the artcileDiscovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies, Application In Synthesis of 2057507-56-7, the publication is Journal of Medicinal Chemistry (2020), 63(24), 15564-15590, database is CAplus and MEDLINE.

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

Journal of Medicinal Chemistry published new progress about 2057507-56-7. 2057507-56-7 belongs to pyrazoles-derivatives, auxiliary class Pyrazoles, name is 3-Bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, and the molecular formula is C8H11BrN2, Application In Synthesis of 2057507-56-7.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Karlsson, Staffan published the artcileFrom Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations, HPLC of Formula: 2057507-56-7, the publication is Organic Process Research & Development (2022), 26(3), 601-615, database is CAplus.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line ¹H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

Organic Process Research & Development published new progress about 2057507-56-7. 2057507-56-7 belongs to pyrazoles-derivatives, auxiliary class Pyrazoles, name is 3-Bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, and the molecular formula is C8H11BrN2, HPLC of Formula: 2057507-56-7.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics

Bebbington, David published the artcileThe discovery of the potent aurora inhibitor MK-0457 (VX-680), HPLC of Formula: 851435-28-4, the publication is Bioorganic & Medicinal Chemistry Letters (2009), 19(13), 3586-3592, database is CAplus and MEDLINE.

The identification of a novel series of Aurora kinase inhibitors and exploitation of their SAR is described. Replacement of the initial quinazoline core with a pyrimidine scaffold and modification of substituents led to a series of very potent inhibitors of cellular proliferation. MK-0457 (I) has been assessed in Phase II clin. trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph + ALL) containing the T315I mutation.

Bioorganic & Medicinal Chemistry Letters published new progress about 851435-28-4. 851435-28-4 belongs to pyrazoles-derivatives, auxiliary class Imidazole,Pyrimidine,Chloride,Amine, name is 2-Chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, and the molecular formula is C9H10ClN5, HPLC of Formula: 851435-28-4.

Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics